C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Purchases 17,983 Shares of Pfizer Inc. $PFE

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its position in shares of Pfizer Inc. (NYSE:PFE) by 150.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,929 shares of the biopharmaceutical company’s stock after buying an additional 17,983 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in Pfizer were worth $745,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of PFE. Franklin Resources Inc. lifted its stake in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Neuberger Berman Group LLC grew its stake in Pfizer by 203.8% during the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after purchasing an additional 6,045,763 shares during the period. Ameriprise Financial Inc. increased its holdings in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock worth $468,174,000 after purchasing an additional 5,978,927 shares in the last quarter. AQR Capital Management LLC increased its holdings in Pfizer by 120.9% in the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company’s stock worth $230,986,000 after purchasing an additional 5,202,884 shares in the last quarter. Finally, Amundi lifted its stake in Pfizer by 10.8% in the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after buying an additional 4,043,413 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Finally, Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $28.19.

Pfizer Price Performance

PFE stock opened at $28.37 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The business has a 50-day simple moving average of $27.09 and a two-hundred day simple moving average of $25.83. The company has a market capitalization of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $0.63 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.